Navigation Links
Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Federal Award to Risperdal Whistleblower
Date:11/29/2013

New York, New York (PRWEB) November 29, 2013

As Risperdal lawsuits (http://www.risperdallawsuitcenter.com/ ) continue to move forward in courts around the country, Bernstein Liebhard LLP notes that the federal government has granted a substantial award to a whistleblower who provided the U.S. Department of Justice with important information regarding Johnson & Johnson’s marketing of Risperdal. According to a report from the Chicago Tribune, information provided by the 74-year-old retired pharmacist aided in a Justice Department investigation that ultimately resulted in a $2.2 billion settlement with Johnson & Johnson. The Risperdal whistleblower, along with others who provided information vital to the governments’ investigation, will share in a $27.5 million portion of that settlement.*

“Information provided by whistleblowers is often the only way serious wrongdoing on the part of corporations comes to light. The information used in the government’s investigation could also provide important evidence in lawsuits that allege a link between the use of Risperdal and gynecomastia, or male breast growth,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Risperdal lawsuit consultations to any individual who may have developed gynecomastia due to their use of the drug.

Risperdal and Gynecomastia
The Johnson & Johnson settlement was announced by the Justice Department on November 4, 2013. Among other things, the government had charged that Risperdal was marketed for pediatric uses long before the U.S. Food & Drug Administration (FDA) approved such indications in 2006. Federal prosecutors also charged that the company knew that Risperdal posed serious risks to children, including an association with male breast growth. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

According to court documents in the case, Johnson & Johnson and its Janssen Pharmaceuticals unit agreed to plead guilty to a criminal misdemeanor that it illegally marketed Risperdal for use in elderly dementia patients. However, the companies did not admit to any misconduct in resolving civil charges involving the marketing of the antipsychotic drug for use in children. The $2.2 billion settlement includes criminal fines and forfeiture of $485 million and civil penalties of $1.72 billion.

According to court documents, at least 250 Risperdal lawsuits are currently pending in a consolidated litigation underway in the Philadelphia Court of Common Pleas in Pennsylvania, all of which were filed on behalf of individuals who were allegedly harmed by the drug. A number of these claims involve allegations of a link between Risperdal and gynecomastia. (Risperdal Litigation, case number 100300296)

Alleged victims of Risperdal and gynecomastia may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. For more information on filing a Risperdal lawsuit, please visit Bernstein Liebhard LLP’s website. For a free, no-obligation review of your case, please call 800-511-5092.

  • articles.chicagotribune.com/2013-11-04/business/ct-biz-1105-jnj-side-20131105_1_johnson-johnson-risperdal-controversial-federal-anti-fraud-law, Chicago Tribune, November 4, 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author

Read the full story at http://www.prweb.com/releases/risperdal-lawsuit/risperdal-gynecomastia/prweb11377428.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Parker Waichman LLP Commends Arkansas Attorney General for Backing Fine Against Johnson & Johnson over Risperdal Off-Label Marketing Allegations
2. The Consumer Justice Foundation Launches RisperdalLaw.com, an Informational Web Site Dealing with Alleged Risperdal Side Effects Including Gynecomastia
3. Bernstein Liebhard LLP Investigating Risperdal Lawsuits on Behalf of Victims of Male Breast Growth Allegedly Caused by Risperdal
4. New Risperdal Lawsuit Filed in Pennsylvania Litigation; Alleges Male Breast Growth Injuries Caused by Anti-Psychotic Medication, Bernstein Liebhard LLP Reports
5. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Settlement in Risperdal Marketing Investigation
6. Risperdal Lawsuits: $2.2 Billion Settlement Between Federal Government, Johnson & Johnson Over Alleged Illegal Marketing of Risperdal, Other Medications
7. Risperdal Lawsuit News: Johnson & Johnson To Pay Over $2.2 Billion In Risperdal and Invega Settlement Draws Comment From Wright & Schulte LLC
8. J&J to Pay $2.2B to Settle Allegations Over Its Marketing of Risperdal; Parker Waichman LLP Applauds Efforts of Whistleblowers in Helping Compel Resolution
9. Risperdal Lawsuit News: Rottenstein Law Group LLP Comments on $2 Billion Risperdal Settlement Report
10. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Mounting Claims Involving Risperdal Gynecomastia Allegations in Pennsylvania Litigation
11. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Release of Emails from Johnson & Johnson’s Janssen Subsidiary in Federal Risperdal Settlement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... 31, 2016 , ... Throughout the day, adults often find themselves reaching for a cup of ... they could be reaching for instead is a cup of Matcha green tea. Matcha is ... This sacred tea is harvested from early June to mid-July, when the leaves are the ...
(Date:5/31/2016)... ... May 31, 2016 , ... Presence Technology ... has been included by Gartner, Inc. in the Contact Center Infrastructure Magic Quadrant ... Center Infrastructure technologies, some of which include: Computer-telephony integration (CTI)/Web services interfaces, ...
(Date:5/31/2016)... ... 31, 2016 , ... St. Joseph Medical Center (SJMC) announced ... which enables physicians at SJMC’s two hospital campuses, downtown and in the Heights, ... the exchange. SJMC’s membership in the health information exchange underscores the hospital’s commitment ...
(Date:5/31/2016)... ... 31, 2016 , ... The University of Tennessee Medical Center ... the latest in Clinical Patient Pod (CPP) technologies provided through Jvion’s ... into the clinical workflow. These insights are empowering the more than 30 case ...
(Date:5/31/2016)... Prairie, MN (PRWEB) , ... May 31, 2016 , ... ... from the American Association for Laboratory Accreditation (A2LA) to include ISO 594-1 and ISO ... most common means of achieving a leak-free connection between two medical devices (e.g. a ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... study highlights the necessity of health literacy within the technology advancement of diagnostic imaging. According ... , a majority of oncology patients undergo imaging screenings without understanding the nuanced risks ... ... ... Medical Diagnostic Imaging Ampronix ...
(Date:5/27/2016)... May 27, 2016 According to ... hypertension is driving ambulatory blood pressure monitoring system market ... and their ability to respond to different pressure rates, ... can lead to various cardiovascular disorders such as heart ... These diseases are growing in prevalence each year. WHO ...
(Date:5/27/2016)... 27, 2016 Kitov ... focused on late-stage drug development, today announced the ... of pivotal batches required for registration of KIT-302 ... This follows Kitov,s announcement in December ... met its primary efficacy endpoint. "We ...
Breaking Medicine Technology: